No — pooled across 25 studies and 617,479 women, fertility treatment shows no breast-cancer association (OR 0.97, 95% CI 0.90-1.04), and the largest cohort followed 25,108 IVF patients for a median of 21 years and found a risk identical to the general population (SIR 1.01, 0.93-1.09). The theoretical worry about stimulation hormones has been tested at scale and has not held up.
Why Do People Worry That IVF Causes Breast Cancer?
Because breast cancers are often hormone-sensitive and IVF deliberately raises estrogen, the concern is biologically logical — and it is also the single most tested question in reproductive safety. Concerns about IVF and breast cancer have existed since the first IVF births.
The Estrogen Exposure Mechanism
Lifetime estrogen exposure genuinely does shape breast-cancer risk, which is why a treatment that spikes estrogen drew so much scrutiny. Early menarche before age 12, late menopause after 55, hormone replacement therapy and postmenopausal obesity all raise risk through that pathway, so a IVF and breast cancer link was a reasonable hypothesis rather than a fringe fear.
What IVF adds is supraphysiologic estradiol — but only for the days of a stimulation cycle. The decisive question was never whether estrogen rises; it was whether a two-week rise can accumulate into a decades-long signal, and the cohorts below are what answering that looks like.
Why Does Exposure Duration Matter?
The distinguishing variable is time, not hormone. IVF exposure is short-term — 10-14 days per cycle, with a mean of 3.6 cycles in the Dutch cohort — while the established natural risk factors represent years or decades of cumulative endogenous estrogen.
| Factor | Estrogen exposure | What cohort data show |
|---|---|---|
| IVF stimulation (per cycle) | 10-14 days | OMEGA: 25,108 women, mean 3.6 cycles, SIR 1.01 (0.93-1.09) |
| Hormone replacement therapy | Years | Established modest risk increase |
| Early menarche (before 12) | Decades of endogenous estrogen | Confirmed risk factor |
| Late menopause (after 55) | Additional years of endogenous estrogen | Confirmed risk factor |
Does IVF Increase Breast Cancer Risk? What the Large Cohorts Show
Three population-based cohorts — the Netherlands, Denmark and Israel — cover more than 670,000 women and reach nearly the same answer, with one nuance about age.
Dutch OMEGA cohort (JAMA 2016): 25,108 women treated between 1980 and 1995 (mean age 32.8 years, mean 3.6 IVF cycles) were followed for a median of 21.1 years, during which 839 invasive and 109 in-situ breast cancers appeared. Risk matched the general population (SIR 1.01, 95% CI 0.93-1.09) and matched subfertile women who never had IVF (HR 1.01, 0.86-1.19).
Cumulative incidence at age 55 was 3.0% after IVF versus 2.9% without it (P = .85), and looking back 20 or more years after treatment the standardized incidence ratio was 0.92 (0.73-1.15).
Danish DANAC II cohort (Human Reproduction 2021): this is the study that found a signal — 61,579 ART-treated women versus 579,760 age-matched untreated women, with 695 versus 5,166 breast cancers over a median of 9.7 years among treated women (1.1% vs 0.9%, P < 0.0001). Adjusted for nulliparity, education, partnership status, calendar year, maternal breast cancer and age, ART carried a hazard ratio of 1.14 (95% CI 1.12-1.16).
The elevation concentrated in women who started treatment at 40 or older (HR 1.37, 1.29-1.45) and persisted even against the strictest comparator — women whose first birth also came at 40+ (HR 1.51, 1.09-2.08).
Israeli Maccabi cohort (Human Reproduction 2022): 32,366 ART patients were each matched one-to-one with a woman treated by non-ART assisted reproduction and with one woman from the general population; 984 (1.0%) developed breast cancer over a mean of 9.1 years. Incidence ran 11.9 per 10,000 person-years after ART versus 10.7 in both comparison groups (ART vs general population HR 1.10, 0.94-1.28; ART vs non-ART treatment HR 1.00, 0.86-1.16).
The authors flagged the mirror-image limitation to the Danish data: the cohort averaged only 42 years of age at the end of follow-up, so it could not detect a postmenopausal difference.
What Do the Meta-Analyses Conclude?
Four independent syntheses — 25, 20, 8 and 8 studies — land between 0.89 and 1.05, every confidence interval straddling 1.0.
| Meta-analysis | Evidence pooled | Breast-cancer estimate |
|---|---|---|
| Cullinane et al., BJS Open 2022 | 25 studies, 617,479 women | OR 0.97 (95% CI 0.90-1.04) |
| Gennari et al., Breast Cancer Research and Treatment 2015 | 20 population-based cohort studies, 207,914 women, 2,347 cancers | SRR 1.05 (0.96-1.14); IVF-only subset 0.96 (0.80-1.14) |
| Li et al., International Journal of Gynecological Cancer 2013 | 8 cohort studies, 746,455 participants | RR 0.89 (0.79-1.01) |
| Liu et al., Frontiers in Endocrinology 2022 | 8 studies in genetically susceptible women | BRCA carriers OR 1.02 (0.74-1.40) |
Two nuances matter more than the pooled numbers. Gennari’s group found a standardized ratio of 1.13 (1.02-1.26) in studies with at least 10 years of follow-up against 0.95 (0.85-1.06) in shorter studies, and an elevated 1.26 (1.06-1.50) in the older non-IVF, clomiphene-based studies — but no increase at all in the IVF subset.
“This meta-analysis did not find a significant association between fertility treatments and excess breast-cancer risk. Women considering IVF should be informed that it does not appear to increase breast-cancer risk.” — Cullinane et al., BJS Open, 2022
Is IVF Safe for BRCA Mutation Carriers?
The available data show no added risk, but they are too sparse to settle the question. The only meta-analysis aimed specifically at genetically susceptible women pooled 5 cohort and 3 case-control studies and found BRCA carriers who had fertility treatment at an odds ratio of 1.02 (95% CI 0.74-1.40) — no signal, but a wide interval.
Inside that pooled estimate, BRCA1 carriers came in at OR 1.18 (0.81-1.72), BRCA2 carriers at OR 0.54 (0.09-3.34), women treated with IVF at OR 0.75 (0.51-1.10), and clomiphene users at OR 1.07 (0.78-1.45). Women with a family history but no identified mutation sat highest at OR 1.35 (0.97-1.89), which the authors still reported as non-significant and called a reason for larger prospective cohorts.
The Israeli cohort adds a different kind of reassurance: among the women who did develop breast cancer, BRCA1/2 mutation prevalence and tumour stage did not differ between ART patients, non-ART fertility patients and the general population. Most cancer centers still support IVF for BRCA carriers under appropriate monitoring, and a joint consultation with a genetic counselor and a reproductive endocrinologist before treatment remains standard practice.
Do More IVF Cycles Mean Higher Risk?
No — in every dataset that tested dose, more cycles tracked with the same or a lower risk, which is strong evidence against a causal link.
- Dutch OMEGA: women who underwent 7 or more IVF cycles had lower breast-cancer risk than those with 1-2 cycles (HR 0.55, 0.39-0.77).
- Israeli Maccabi: no correlation between breast-cancer risk and the number of ART cycles, or between risk and recombinant versus urinary medications.
- Pooled evidence: Cullinane’s 25-study meta-analysis reports no increased risk for women receiving six or more IVF cycles, and none at beyond-10-year follow-up (OR 0.97, 0.85-1.12).
If you want to understand what each cycle involves, see our step-by-step IVF process guide.
Does Age at First Treatment Change Anything?
Yes — age at treatment initiation is the most consistent modifier in this literature. The Danish cohort found risk rising with age, peaking for women who began ART at 40 or older (HR 1.37, 1.29-1.45).
The other two cohorts cannot contradict that but cannot confirm it either: OMEGA’s women averaged 32.8 years at baseline and showed no rise even 20 years on, while the Israeli cohort’s members were too young at the end of follow-up to address postmenopausal risk. For a broader look at how age drives treatment decisions, see what affects IVF success rates.
Does the Infertility Diagnosis Itself Affect Risk?
Baseline patient factors move risk more than the treatment does. In the DANAC II analysis every cause of infertility was slightly associated with post-treatment breast cancer, and within OMEGA, women who responded poorly to their first cycle (fewer than 4 oocytes collected) ended up at lower risk (HR 0.77, 0.61-0.96) — a marker of who carries a pregnancy, not of hormone damage.
In the same Dutch center’s 24-year endometrial-cancer follow-up, obesity and endometriosis raised risk irrespective of ART treatment, while parity and oral-contraceptive use lowered it. Related reading: our PCOS fertility guide and endometriosis fertility guide.
Can Breast Cancer Survivors Still Have Children with IVF?
Yes — fertility preservation before cancer treatment is standard practice, and the largest prospective dataset on the question now runs past five years. Full details are in our egg freezing guide.
The core protocol adjustments:
- Timing: egg or embryo freezing happens before chemotherapy whenever the treatment window allows; in the POSITIVE trial, 180 of 497 women (36%) had already cryopreserved embryos or oocytes before enrolling.
- Letrozole-coordinated stimulation: for hormone-receptor-positive cancers, letrozole-based protocols are the usual choice because they avoid the sustained supraphysiologic estradiol of a conventional high-dose gonadotropin cycle.
- GnRH agonist trigger: an agonist instead of an hCG trigger cuts severe ovarian hyperstimulation dramatically (Cochrane review, 17 randomized trials, n = 1,847; OR 0.15, 0.05-0.47) and is paired with freeze-all to protect live birth.
- Frozen embryo transfer: survivors typically transfer later, once oncologic treatment and endocrine-therapy decisions are settled, rather than in a stimulated fresh cycle.
The American Society for Reproductive Medicine, ASRM publishes clinical guidance on oncofertility, and the CDC’s ART program tracks treatment outcomes nationally. To find clinics offering fertility preservation services, browse our clinic directory.
Is Pregnancy Safe After Breast Cancer Treatment?
Yes on short- and medium-term evidence, with the caveat that late recurrence remains the open question. The POSITIVE trial (New England Journal of Medicine 2023;388:1645-1656) enrolled 516 young women with earlier hormone-receptor-positive breast cancer — median age 37 years, 93.4% stage I or II — who paused adjuvant endocrine therapy after 18-30 months to attempt pregnancy.
Among the 497 women followed for pregnancy, 368 (74.0%) conceived at least once, 317 (63.8%) had at least one live birth, and 365 babies were born. At 1,638 patient-years of follow-up, 44 breast-cancer events had occurred, below the prespecified 46-event safety threshold, and the 3-year incidence matched the external control cohort: 8.9% (95% CI 6.3-11.6) versus 9.2% (7.6-10.8).
A preplanned 2026 update (Annals of Oncology 2026;37:1230-1241) extended that median follow-up to 71 months for the 518 eligible women. Five-year breast-cancer-free-interval events were 12.3% in POSITIVE versus 13.2% in matched SOFT/TEXT controls (difference -0.9%, 95% CI -4.2% to 2.6%), and distant recurrence was 6.2% versus 8.3% (-2.1%, 95% CI -4.5% to 0.4%).
By then 377 of 497 women (76%) had documented at least one pregnancy and 343 (69%) at least one live birth, for 440 offspring. Among the 180 women who had cryopreserved material before enrollment, the 5-year event incidence was 14.0% versus 11.5% in an unadjusted comparison — which the investigators read as fertility preservation being safe, with the confounding acknowledged.
A Survivor’s Story: Freezing Eggs Before Chemotherapy
The story below is shared with consent; identifying details have been changed to protect privacy, and individual protocols vary.
A 33-year-old patient, hormone-receptor-positive stage II breast cancer. Before chemotherapy she completed one egg-freezing cycle on a letrozole-coordinated protocol and successfully vitrified 9 mature eggs. After chemotherapy and 18 months of endocrine therapy she returned for a frozen embryo transfer.
“My oncologist and fertility specialist coordinated the schedule week by week. Knowing I had frozen eggs made the whole cancer treatment easier to bear,” she said. She is now 20 weeks pregnant.
FAQ
Q: Does IVF directly cause breast cancer?
No — the pooled estimate across 25 studies and 617,479 women is OR 0.97 (95% CI 0.90-1.04), and the longest-running cohort found SIR 1.01 (0.93-1.09) after 21 years. The theoretical hormone concern has not been confirmed by any large clinical dataset.
Q: Should I freeze my eggs before breast cancer treatment?
Yes — discuss egg or embryo freezing with your oncology team before chemotherapy starts, since stimulation can usually be completed in one cycle. In the POSITIVE trial, 180 of 497 enrolled women (36%) had already frozen embryos or oocytes beforehand, and their 5-year recurrence experience did not differ meaningfully from women who had not (14.0% vs 11.5%, unadjusted).
Many major cancer centers run dedicated oncofertility programs (see the egg freezing guide).
Q: Can BRCA carriers safely do IVF?
Current evidence does not show added risk, but the numbers are thin: the only meta-analysis of genetically susceptible women found OR 1.02 (0.74-1.40) for BRCA carriers overall and OR 1.18 (0.81-1.72) for BRCA1 specifically. Because those intervals are wide, a pre-treatment conversation with a genetic counselor is still the standard recommendation.
Q: Does IVF increase the risk of other cancers?
Not consistently, and where signals appear they track with subfertility rather than stimulation. In the Dutch cohort at a median of 24 years, ovarian cancer was raised against the general population (SIR 1.43, 1.18-1.71) but not against subfertile women who never had ART (HR 1.02, 0.70-1.50); endometrial cancer was not significantly raised on either comparison (SIR 1.19, 0.97-1.44).
Borderline ovarian tumors are the honest exception: SIR 2.20 (1.66-2.86) and HR 1.84 (1.08-3.14), though with no dose-response across cycle number. An 8-cohort meta-analysis of 746,455 women reported ovarian RR 1.59 (1.24-2.03) and cervical RR 1.07, while a 2024 meta-analysis of 28 cohort studies reported ovarian RR 1.33 (1.05-1.69) and cervical RR 0.67 (0.46-0.97) — mixed directions, no syndrome.
Q: Can women with hormone-sensitive breast cancer undergo IVF?
Yes, using modified protocols — letrozole-coordinated stimulation avoids the sustained estradiol peak of conventional gonadotropins, and frozen embryo transfer defers pregnancy until oncologic treatment is complete. The POSITIVE trial is the prospective evidence that pausing endocrine therapy afterwards did not raise recurrence: 8.9% versus 9.2% of matched controls at three years.
New to treatment? Start with our beginner’s guide to what IVF is.
Q: Do I need extra breast screening after IVF?
No IVF-specific screening schedule exists, and none of the cohorts above enrolled women on that basis. What does change the conversation is age at treatment: the Danish signal appeared in women starting ART at 40+ (HR 1.37, 1.29-1.45), so tell your clinician when you were treated and have your routine screening plan set from your own history and family risk.
Q: Do fertility drugs alone raise breast cancer risk?
The drug question splits by era and by route. Gennari’s meta-analysis found no increase in the IVF subset (SRR 0.96, 0.80-1.14) but an elevated SRR of 1.26 (1.06-1.50) across three studies of older non-IVF, clomiphene-based treatment, and its authors discouraged long-term clomiphene use outside current indications.
Cullinane’s 25-study synthesis found no excess risk for clomiphene, hCG, gonadotropin analogues or progesterone examined individually, and Liu’s susceptible-women analysis put clomiphene at OR 1.07 (0.78-1.45) and gonadotropins at OR 1.32 (0.80-2.18) — both non-significant.
How This Article Was Written
This guide was compiled by the ProIVF Medical Editorial Team from a systematic review of peer-reviewed cohort studies, meta-analyses and clinical-trial reports. Every figure in the body comes from the primary source listed below — we verified each one against the PubMed record rather than a secondary summary, and dropped claims that we could not trace.
Context on national treatment volumes and outcomes comes from the Society for Assisted Reproductive Technology, SART outcomes reporting and the CDC’s ART success-rate program; UK registry context from the Human Fertilisation and Embryology Authority, HFEA. The ProIVF Medical Advisory Board reviewed it for clinical accuracy, and it will be updated when new long-term evidence changes the picture.
Sources
- van den Belt-Dusebout AW, Spaan M, Lambalk CB, et al. JAMA 2016;316:300-312. PubMed
- Vassard D, Pinborg A, Kamper-Jørgensen M, et al. Hum Reprod 2021;36:3152-3160. PubMed
- Machtinger R, Fallach N, Goldstein I, et al. Hum Reprod 2022;37:577-585. PubMed
- Cullinane C, Gillan H, Geraghty J, et al. BJS Open 2022;6:zrab149. PubMed
- Gennari A, Costa M, Puntoni M, et al. Breast Cancer Res Treat 2015;150:405-413. PubMed
- Li LL, Zhou J, Qian XJ, Chen YD. Int J Gynecol Cancer 2013;23:16-24. PubMed
- Liu X, Yue J, Pervaiz R, et al. Front Endocrinol (Lausanne) 2022;13:986477. PubMed
- Partridge AH, Niman SM, Ruggeri M, et al. N Engl J Med 2023;388:1645-1656. PubMed
- Pagani O, Niman SM, Ruggeri M, et al. Ann Oncol 2026;37:1230-1241. PubMed
- Spaan M, van den Belt-Dusebout AW, Lambalk CB, et al. J Natl Cancer Inst 2021;113:699-709. PubMed
- Spaan M, van den Belt-Dusebout AW, Lambalk CB, et al. Hum Reprod 2025;40:739-749. PubMed
- Chen C, Shi H, Yang J, et al. Crit Rev Oncol Hematol 2024;197:104320. PubMed
- Youssef MA, Van der Veen F, Al-Inany HG, et al. Cochrane Database Syst Rev 2014;(10):CD008046. PubMed
The Bottom Line on IVF and Breast Cancer
Two decades of cohort follow-up converge on one answer: IVF does not increase breast cancer risk. The three largest investigations — the Dutch OMEGA cohort (25,108 women, 21 years, SIR 1.01), the Danish DANAC II cohort (61,579 treated women, HR 1.14) and the Israeli Maccabi cohort (32,366 matched triplets, HR 1.10 against the general population) — sit within a tenth of a point of no effect.
Avoiding needed fertility treatment out of cancer fear is not supported by evidence, and for breast cancer survivors, protocol-adjusted IVF followed by the POSITIVE trial’s pregnancy data is a realistic path to parenthood.
If you have a personal or family history of breast cancer, consult both a reproductive endocrinologist and an oncologist before starting — the one consistently modified variable in this literature is the age at which treatment begins. Browse HFEA- and CDC-reporting clinics or contact our team for personalized guidance.
Last updated: September 20, 2026. This article is for informational purposes only and does not constitute medical advice; cancer risk assessment should be performed by qualified medical professionals. Verify all clinical information with your care team before making treatment decisions, and tell us if you spot anything inaccurate.
